What Calan Treats: Main Uses and Benefits

Calan, which contains the active ingredient verapamil, belongs to a class of medications known as calcium channel blockers. It works by influencing the movement of calcium into the muscle cells of the heart and blood vessels. This action results in the relaxation of blood vessels and a decrease in the workload of the heart.

Primary Uses

Hypertension (High Blood Pressure)

Calan is frequently used to manage high blood pressure. By relaxing and widening the blood vessels, the medication allows blood to flow more easily throughout the body. Lowering blood pressure is a key component in long-term cardiovascular health management.

Angina Pectoris (Chest Pain)

This medication is utilized to manage chronic stable angina and vasospastic angina. It helps increase the supply of oxygen-rich blood to the heart muscle while simultaneously reducing the heart's demand for oxygen. This dual action helps decrease the frequency and severity of chest pain episodes.

Cardiac Arrhythmias

Calan is effective in controlling certain types of irregular heart rhythms, particularly those originating in the upper chambers of the heart (atria). It helps stabilize the heart rate by slowing the electrical impulses that coordinate the heartbeat. Specifically, it is used for:

• Controlling the heart rate in patients with atrial fibrillation or atrial flutter.
• Treating and preventing paroxysmal supraventricular tachycardia (PSVT).

Benefits in Management

• Vascular Relaxation: By preventing the constriction of blood vessels, it assists in maintaining smoother systemic circulation.
• Heart Rate Regulation: It provides a mechanism to prevent the heart from beating too rapidly, which can improve overall cardiac efficiency.
• Improved Oxygen Balance: By reducing the effort required for the heart to pump, it helps ensure the heart muscle operates within its available oxygen supply.

Regulatory References

1. Health Canada Product Monograph

Who Can and Cannot Use Calan (Verapamil)?

The eligibility for Calan is defined by strict regulatory criteria concerning pre-existing conditions and specific population groups.

Absolute Contraindications (Must Not Use) Verapamil is contraindicated in patients with:

• Severe left ventricular dysfunction (e.g., ejection fraction less than 30%) or Cardiogenic Shock.
• Hypotension (systolic pressure less than 90 mm Hg).
• Sick Sinus Syndrome or Second- or Third-Degree AV Block (unless a functioning artificial pacemaker is present).
• Atrial Flutter or Atrial Fibrillation with an accessory bypass tract (e.g., Wolff-Parkinson-White syndrome).

Population Restrictions and Conditional Use	Area	Regulatory Status
Hepatic Function	Use requires caution; dose reduction (up to one-third of the normal oral daily dose) is necessary for patients with impaired function.
Renal Function	Use with caution and close monitoring for excessive effects is advised.
Pediatric Use	Safety and effectiveness have not been established for the oral forms.
Geriatric Use	Use is allowed, but lower initial doses may be warranted due to age-related organ changes.
Pregnancy	Classified as Category C; use only if potential benefit justifies the potential risk to the fetus.
Lactation	Verapamil is excreted into human milk; the decision to discontinue nursing or discontinue the drug should consider possible infant exposure.

This profile establishes the defined adult population permitted to use the medicine and formally excludes patients with specific, severe cardiac conduction and hemodynamic issues.

Calan Interactions with other medicines and products

The interaction profile for verapamil (Calan), as detailed in government regulatory sources, is structured around its potential to alter the concentrations of co-administered medicines and create additive cardiovascular effects. This information is descriptive and non-advisory.

---

Official Regulatory Interaction Information

Category	Official Regulatory Information for Calan (Verapamil)
Medicinal product categories with documented interactions	Beta-Blockers (oral and IV), Antiarrhythmics, CYP3A4 inhibitors, CYP3A4 inducers, HMG-CoA Reductase Inhibitors (Statins), Digitalis Glycosides, mTOR Inhibitors
Mechanistic basis of interactions (only if stated in label)	Pharmacokinetic: Verapamil is a documented inhibitor of the CYP3A4 enzyme and the efflux transporter P-glycoprotein (P-gp). Pharmacodynamic: Interactions can result from additive depressant effects on myocardial contractility and/or AV conduction.
Timing-based interaction rules	Intravenous Beta-Blockers: Must not be administered in close proximity (within a few hours) of intravenous verapamil. Disopyramide: Must not be administered within 48 hours before or 24 hours after verapamil administration.

---

Official Interaction Statements

• Co-administration with intravenous beta-blockers is formally prohibited in close proximity due to the risk of severe cardiovascular depression.
• Verapamil significantly increases the serum concentration of Digoxin (by 50% to 75%), which is stated to necessitate a reduction in the Digoxin dose.
• Verapamil increases the plasma exposure of certain statins, such as Simvastatin, leading to restrictions where the Simvastatin dose should not exceed 10 mg daily.
• The co-ingestion of grapefruit juice may significantly increase verapamil plasma concentrations, as noted in the official labeling.
• Verapamil inhibits ethanol (alcohol) elimination, resulting in elevated blood alcohol levels and increased effects.

---

The regulatory documents define the verapamil interaction structure based on its roles as a CYP3A4/P-gp inhibitor and as an agent with potent pharmacodynamic effects on the heart. This dual influence necessitates explicit label constraints, including contraindicated combinations and mandatory dose adjustments or timing separation for many co-administered substances.

How Calan Works

Calan (verapamil) functions as a non-dihydropyridine antagonist of the L-type voltage-dependent calcium channels found in cardiac tissue and vascular smooth muscle. This interaction modulates essential biological processes that govern heart activity and systemic resistance.

Modulating Vascular Resistance

This domain covers the drug's effect on arterial smooth muscle cells, where the blockage of L-type calcium channels prevents the influx of calcium ions necessary for cellular contraction. This mechanism leads directly to the relaxation and widening of the arteries (vasodilation), which results in a reduction of peripheral resistance to blood flow.

Dampening Myocardial Contractility

This mechanistic domain focuses on the heart muscle cells (myocytes). By interfering with calcium entry, the drug modifies the early molecular steps that initiate muscle shortening. This results in a reduced force of heart muscle contraction, which subsequently leads to a decrease in myocardial oxygen consumption.

Altering Cardiac Electrical Conduction

This mechanism selectively targets the sinoatrial (SA) and atrioventricular (AV) nodes—the heart's primary electrical centers. Blocking calcium channels in these cells alters the rate at which electrical signals are generated and conducted. This action modifies the rate of electrical signal generation and propagation, resulting in a decreased heart rate and slower conduction speed.

Official Administration Guidelines

Calan (verapamil) is administered through two primary, officially approved routes: oral for tablets and capsules, and intravenous (IV) injection for a sterile solution. The route of use is structured by the need for immediate action; the IV form is reserved for acute clinical settings requiring continuous supervision, while the oral forms are used for chronic, ongoing therapy.

The dosing schedule is determined by the formulation. Immediate-Release (IR) tablets require multiple daily doses to maintain consistent levels, typically administered two to four times a day, with the maximum total daily dose generally not exceeding 480 mg. Extended-Release (ER/SR) forms are usually taken once daily to facilitate consistent drug delivery over a prolonged period.

Practical administration conditions are explicitly documented. Oral tablets should generally be taken with food or milk to aid proper intake. The ER/SR tablets must be swallowed whole and must not be crushed or chewed, as this compromises the extended-release design. The IV injection must be administered slowly over a period of at least two minutes; for older adults, the administration time is often extended to at least three minutes. Furthermore, official guidance requires a substantial dose reduction for patients with significant hepatic impairment and cautions that if a dose is missed, the next dose should be taken at the regular scheduled time, without doubling the dose.

Research evidence / Overview of Studies for Calan (Verapamil)

The information below summarizes the types of scientific studies that have been conducted on Calan (verapamil) for its approved uses. This overview focuses strictly on the evidence structure reported in authoritative sources and does not provide clinical advice or recommendations for its use.

Evidence for use in Essential Hypertension (High Blood Pressure)

Research for verapamil's use in essential hypertension explored populations based on Randomized Controlled Trials (RCTs), comparative studies, and meta-analyses. These trials were applied in adult populations, including older adults and those with other heart conditions like Coronary Artery Disease (CAD).

Researchers examined outcomes related to systemic or functional imbalance, mainly monitoring the reduction in systolic and diastolic blood pressure (BP). Long-term studies were conducted, and studies monitored the pattern of major cardiovascular events, including stroke and heart attack, over extended time intervals. Comparative trials explored how the rate of blood pressure change achieved with a verapamil-based strategy compared with strategies based on other antihypertensive drug classes. Data show patterns related to the achievement of blood pressure goals that were measured during the study period.

What is still uncertain is that while research has evaluated measurements of blood pressure levels in observed populations, research is limited in dedicated large-scale RCTs comparing verapamil directly to a placebo to determine outcomes related to long-term mortality and morbidity in otherwise uncomplicated hypertension patients. Therefore, evidence quality varies across studies, with consistent data for research on changes in blood pressure measures, but data are still emerging for long-term outcomes related to major events compared to non-active treatments.

Evidence for use in Chronic Stable Angina (Effort-induced Chest Discomfort)

The evidence for verapamil's evaluation in chronic stable angina, a condition where symptoms may vary in intensity, primarily comes from short-term and intermediate-term Randomized Controlled Trials (RCTs), often using double-blind, crossover designs. These studies were applied in populations examining patient-reported experiences of physical discomfort, specifically focusing on effort-induced chest discomfort.

Studies monitored patient-reported outcomes describing perceived discomfort. Researchers measured functional outcomes like the increase in total exercise duration and the time until symptoms began during standardized stress testing. They also monitored changes in the frequency of anginal episodes and patient-reported consumption of rescue medication. Studies reported measured changes in the frequency of symptoms and in exercise duration when compared to placebo or other treatments during the study.

What remains uncertain is that the follow-up durations were limited in many initial symptomatic trials. This means there is limited information for long-term outcomes on the durability of measured changes in angina symptoms or on measured cardiovascular event rates specifically in patients where angina symptom measurement was the focus.

Evidence for use in Supraventricular Tachycardias (Rapid Heart Rhythms)

Verapamil was studied for the management of conditions characterized by fluctuating or episodic manifestations, such as Paroxysmal Supraventricular Tachycardia (PSVT) and Atrial Fibrillation/Flutter. The research includes both acute intervention trials, often using the intravenous form, and longer-term clinical studies using the oral form for chronic management.

Studies explored outcomes describing episodic or acute changes. In acute settings, studies monitored the rate of conversion to a normal heart rhythm and the time required to achieve heart rate control. For chronic management, studies examined the recurrence rate of rapid heart rhythm episodes. Data show patterns related to measurements of heart rate in the observed populations, and in acute settings, research highlights changes measured during the study period, with findings describe patterns observed in the studies, including the end of the episode.

Evidence is limited for the long-term clinical significance of verapamil in the evaluation of recurrence over many years, as most studies focus on short-term event termination or recurrence frequency over a few months. Data for certain groups, particularly infants and children, remain insufficient, and Regulatory findings reference limitations regarding the use in certain complex, high-risk heart conditions.

Long-term Studies and Durability of Evidence

Long-term follow-up for verapamil is best characterized by large-scale trials, such as the INVEST trial, which included patients with both hypertension and coronary artery disease and observed responses over defined time intervals spanning several years. This research primarily focused on long-term clinical outcomes reflecting functional imbalance, specifically the rate of combined events (e.g., stroke, heart attack, and cardiovascular death) over periods up to 2.7 years or longer in extended follow-up cohorts.

Research describes patterns related to achieving long-term blood pressure control and reports how cardiovascular event rates evolved in the observed populations compared to those treated with other medication strategies. Studies help show what has been observed so far about the sustained nature of the effects measured.

However, long-term effects are not fully established across all indications. Follow-up durations were limited to a few years in the largest RCTs. Research into the durability of angina symptom measurement or the chronic monitoring of heart rhythm episodes over periods exceeding five years relies more heavily on smaller studies or observational data, and certainty remains low in these specific long-term areas.

Evidence in Special Populations and Comorbid Conditions

Research has explored verapamil in various study populations, including older adults (aged ge 50 years) who participated in major hypertension and coronary artery disease trials. Findings indicate that these subgroups were included in the overall long-term observation studies. Other studies have included a limited number of pediatric patients for the acute management of certain supraventricular tachycardias, but these studies often had small sample sizes.

Research provides context but not individual predictions for how verapamil was observed in patients with comorbid conditions like diabetes or kidney function differences, as these groups were analyzed within the framework of larger trials.

Data for certain groups remain insufficient. For instance, specific, dedicated RCTs focusing solely on the geriatric population are limited, and long-term evidence in pediatric populations is highly restricted due to the rarity of the conditions and ethical considerations for large trials. Evidence is limited in pregnant populations.

What is Still Uncertain About the Research

The available research, while comprehensive in certain areas, still contains limitations and gaps. Comparative evidence is lacking in some contexts, such as head-to-head trials against newer medications for hypertension or supraventricular tachycardias. It is not yet clear whether the long-term survival outcomes specifically from chronic stable angina or PSVT were definitively studied by dedicated RCTs.

In addition, results apply only to the populations studied, meaning that findings describe group patterns, not personal outcomes. Small sample sizes and heterogeneity characterize some of the older trials. For patients with a combination of certain severe heart conditions (e.g., severe heart failure) and a rapid heart rhythm, specific data regarding the use of verapamil are critically limited and findings were mixed in some observational studies. The evidence landscape contributes to the understanding of symptom patterns but highlights what is known and what is still uncertain across different clinical situations.

Key Studies & References

1. NICE Guideline: Stable angina: management (NG185) - published 2020

Common questions about Calan (FAQ)

Q: Is Calan the same type of medicine as metoprolol or amlodipine?

A: Calan, which contains verapamil, is classified as a non-dihydropyridine calcium channel blocker and a Class IV antiarrhythmic medicine. According to official drug classifications, this makes it different from metoprolol, which is a beta-blocker, and amlodipine, which is a dihydropyridine calcium channel blocker. Although they may treat similar conditions, they operate on different principles within the heart and blood vessels.

---

Q: What are the most common things people feel when they first start taking Calan?

A: Studies indicate that the most common effects reported by people taking Calan include constipation, headache, and dizziness. Other common experiences are fatigue and peripheral edema (swelling, usually of the ankles or feet). These are the adverse reactions most frequently observed in clinical trials, but not everyone experiences them.

---

Q: Do I need to avoid any specific foods while taking Calan?

A: The official product labeling indicates that co-ingestion of grapefruit juice may significantly increase the concentration of verapamil in the blood. Additionally, the drug administration guidelines generally recommend taking oral tablets with food or milk to aid in proper absorption.

---

Q: Does Calan interact with common over-the-counter pain relievers like ibuprofen?

A: Official regulatory documents list interacting drug classes or specific prescription medicines but do not typically list every specific over-the-counter (OTC) product. Interactions with specific over-the-counter medicines are typically discussed with a healthcare professional based on general drug class principles.

---

Q: Can older adults typically use Calan without major concerns?

A: Use is permitted for older adults. Regulatory documents indicate that lower initial doses may be warranted in this population due to age-related changes that can prolong the drug's elimination half-life. Close observation and consideration for a lower initial dose are documented as necessary.

---

Q: Can Calan cause swelling in the ankles or feet?

A: Yes, official safety information lists peripheral edema as a common adverse reaction. Peripheral edema is the medical term for swelling, most often observed in the ankles or feet. This is listed as a common adverse reaction observed in clinical trial settings.

---

Q: Is it okay to drink alcohol in moderation while taking Calan?

A: Official documents state that verapamil inhibits the elimination of ethanol (alcohol) from the body. This interaction can lead to elevated blood alcohol levels and potentially increased effects from the alcohol itself. This interaction is officially documented in the product information.

---

Q: What are the main differences between Calan and Norvasc (amlodipine)?

A: Both Calan (verapamil) and Norvasc (amlodipine) are categorized as calcium channel blockers (CCBs). However, Calan is a non-dihydropyridine CCB, which primarily influences the heart's rhythm and rate. Norvasc is a dihydropyridine CCB, which primarily influences the blood vessels to lower blood pressure. The official distinction highlights their different primary focuses in the cardiovascular system.

---

Q: How quickly does Calan usually start to work?

A: According to official pharmacokinetic data, the active ingredient in the oral tablet is measured to reach its peak concentration in the bloodstream in approximately one to two hours after administration. Peak concentration in the blood is measured at this time point.

---

Q: Can Calan interact with supplements like St. John's Wort?

A: Regulatory sources indicate that co-administration with the herbal supplement St. John’s Wort may reduce the amount of verapamil available in the body. This is because St. John's Wort has the potential to affect the specific enzymes that metabolize Calan, which could potentially reduce the drug’s intended effect.

---

Q: How long does Calan stay in your system after stopping it?

A: The elimination half-life of verapamil, which is the time measured for half of the drug to be eliminated from the body, is typically reported to range from approximately 4.5 to 12.0 hours after multiple oral doses. Most of the drug is excreted as metabolites within about five days of the last dose.

---

Q: Does Calan affect my ability to drive or operate machinery?

A: Regulatory information advises caution regarding activities that require alertness. Because Calan can cause adverse reactions such as dizziness and hypotension (low blood pressure), these reported effects may impact a person's ability to safely drive or operate complex machinery.

---

Q: Is there a black box warning associated with Calan?

A: Official regulatory documents for Calan do not include a Black Box Warning. A Black Box Warning is the highest level of warning required by the FDA. However, the label does contain important Warnings and Contraindications regarding patients with pre-existing severe heart conditions.

Calan (verapamil hydrochloride) tablets require specific storage conditions to ensure product integrity and must be handled according to strict regulatory guidelines.

Storage Requirements

Storage Environment	Required Condition
Temperature	Controlled Room Temperature: 20 C to 25 C (68 F to 77 F), with permissible excursions between 15 C and 30 C (59 F and 86 F)
Environmental Protection	Protect from light and moisture
Container	Keep in the original container; dispense in a tight, light-resistant container
Child Safety	Keep out of the sight and reach of children

Disposal Requirements

Disposal of unused or expired Calan must strictly adhere to all local and national regulations for pharmaceutical waste. Individuals should consult a healthcare professional regarding the proper disposal methods for any medicine that is no longer needed. Compliance with environmental standards is required when discarding the product.